Now showing items 2150-2169 of 2905

    • Prostate cancer management. 

      Horwich, A (2004-01)
    • Prostate cancer post-prostatectomy radiotherapy: CT vs MRI for vesico-urethral anastomosis target delineation. 

      Lim Joon, D; Lim, A; Schneider, M; Hiew, C-Y; Lawrentschuk, N; Sengupta, S; Foroudi, F; Jenkins, T; Angus, D; Wada, M; Chao, M; Khoo, V (2017-10)
      BACKGROUND: Vesico-urethral anastomosis (VUA) is critical to the clinical target volume (CTV) in post-prostatectomy radiotherapy (PPRT), as it is the commonest site of recurrence. Typically, this is performed on a CT alone ...
    • Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. 

      Luedeke, M; Rinckleb, AE; FitzGerald, LM; Geybels, MS; Schleutker, J; Eeles, RA; Teixeira, MR; Cannon-Albright, L; Ostrander, EA; Weikert, S; Herkommer, K; Wahlfors, T; Visakorpi, T; Leinonen, KA; Tammela, TLJ; Cooper, CS; Kote-Jarai, Z; Edwards, S; Goh, CL; McCarthy, F; Parker, C; Flohr, P; Paulo, P; Jerónimo, C; Henrique, R; Krause, H; Wach, S; Lieb, V; Rau, TT; Vogel, W; Kuefer, R; Hofer, MD; Perner, S; Rubin, MA; Agarwal, AM; Easton, DF; Al Olama, AA; Benlloch, S; PRACTICAL consortium; Hoegel, J; Stanford, JL; Maier, C (2016-12-15)
      Molecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk ...
    • Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. 

      MacInnis, RJ; Antoniou, AC; Eeles, RA; Severi, G; Guy, M; McGuffog, L; Hall, AL; O'Brien, LT; Wilkinson, RA; Dearnaley, DP; Ardern-Jones, AT; Horwich, A; Khoo, VS; Parker, CC; Huddart, RA; McCredie, MR; Smith, C; Southey, MC; Staples, MP; English, DR; Hopper, JL; Giles, GG; Easton, DF (2010-01)
      Familial aggregation of prostate cancer is likely to be due to multiple susceptibility loci, perhaps acting in conjunction with shared lifestyle risk factors. Models that assume a single mode of inheritance may be unrealistic. ...
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; de Reijke, T; Kataja, V (2013-10)
    • Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 

      Horwich, A; Parker, C; Bangma, C; Kataja, V (2010-05)
    • Prostate cancers that 'Wnt' respond to abiraterone. 

      Linch, M; Attard, G (2018-02-01)
    • Prostate epithelial stem cell culture 

      Hudson, DL (KLUWER ACADEMIC PUBL, 2003)
      The prostate gland is the site of the second most common cancer in men in the UK, with 9,280 deaths recorded in 2000. Another common disease of the prostate is benign prostatic hyperplasia and both conditions are believed ...
    • Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 

      Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; Sideris, S; Zafeiriou, Z; Sumanasuriya, S; Smith, AD; Mehra, N; Jayaram, A; Perez-Lopez, R; Mateo, J; Parker, C; Dearnaley, DP; Tunariu, N; Reid, A; Attard, G; de Bono, JS (2016-03-07)
      The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen (PSA) is ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MGEM; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, ATJM; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-03-20)
      This corrects the article DOI: 10.1038/bjc.2017.429.
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01)
      BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Prostate-specific antigen velocity in untreated, localized prostate cancer. 

      Venkitaraman, R; Norman, A; Woode-Amissah, R; Dearnaley, D; Horwich, A; Huddart, R; Parker, C (2008-01)
      OBJECTIVE: To report the results of a prospective study of active surveillance of untreated prostate cancer, with a focus on baseline predictors of prostate-specific antigen (PSA) velocity, as PSA velocity before treatment ...
    • Prostatic pathology reporting in the UK: development of a national external quality assurance scheme 

      Harnden, P; Coleman, D; Moss, S; Kodikara, S; Patnick, J; Melia, J (BLACKWELL PUBLISHING, 2008-01)
      Aims: To develop a baseline picture of prostatic pathology reporting in the UK, identify areas of particular difficulty and assess the feasibility of a national external quality assurance scheme based on prostatic biopsy ...
    • Protein and drug interactions in the minor groove of DNA 

      Moravek, Z; Neidle, S; Schneider, B (2002-03-01)
      Interactions between proteins, drugs, water and B-DNA minor groove have been analyzed in crystal structures of 60 protein-DNA and 14 drug-DNA complexes. It was found that only purine N3, pyrimidine O2, guanine N2 and ...
    • Protein assemblies with palindromic structure motifs 

      Pinotsis, N; Wilmanns, M (BIRKHAUSER VERLAG AG, 2008-10)
      Symmetric DNA sequence motifs allow the formation of palindromic protein/DNA complexes. Although symmetric protein sequence motifs are less common, recent structural discoveries have unraveled a few protein/protein complexes ...
    • Protein coalitions in a core mammalian biochemical network linked by rapidly evolving proteins 

      Ainali, C; Simon, M; Freilich, S; Espinosa, O; Hazelwood, L; Tsoka, S; Ouzounis, CA; Hancock, JM (BIOMED CENTRAL LTD, 2011-05-25)
      Background: Cellular ATP levels are generated by glucose-stimulated mitochondrial metabolism and determine metabolic responses, such as glucose-stimulated insulin secretion (GSIS) from the beta-cells of pancreatic islets. ...
    • Protein identification and quantification by two-dimensional infrared spectroscopy: Implications for an all-optical proteomic platform 

      Fournier, F; Gardner, EM; Kedra, DA; Donaldson, PM; Guo, R; Butcher, SA; Gould, IR; Willison, KR; Klug, DR (NATL ACAD SCIENCES, 2008-10-07)
      Electron-vibration-vibration two-dimensional coherent spectroscopy, a variant of 2DIR, is shown to be a useful tool to differentiate a set of 10 proteins based on their amino acid content. Two-dimensional vibrational ...
    • The proteolytic release of genotoxins from cooked beef 

      Martin, FL; Cole, KJ; Phillips, DH; Grover, PL (2002-05-24)
      Dietary factors are important in the aetiology of human cancer and carcinogens, mostly heterocyclic aromatic amines, have been isolated from cooked proteinaceous foodstuffs. Whilst such carcinogens have induced tumours in ...